U.S. health regulators have approved the first gene therapy for hemophilia, a blood-clotting disorder with few treatment options. fba hemophilia kprc2 click2houston health us
FILE - The U.S. Food and Drug Administration building stands behind an FDA logo at a bus stop on the agency's campus on Aug. 2, 2018, in Silver Spring, Md. The U.S. health regulators on Tuesday, Nov. 22, 2022, have approved the first gene therapy for hemophilia, a $3.5 million treatment that paves the way for new options in treating the blood-clotting disorder. – U.S. health regulators on Tuesday approved the first gene therapy for hemophilia, a $3.
Like most medicines in the U.S., most of the cost of the new treatment will be paid by insurers — not patients — including private plans and government programs.rare inheritable diseases The agency did not specify how long the treatment works. But CSL Behring said patients should benefit— in terms of reduced bleeding and increased clotting — for years.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
$3.5M gene therapy for hemophilia gets FDA approvalU.S. health regulators have approved the first gene therapy for hemophilia, a blood-clotting disorder with few treatment options.
Read more »
$3.5M gene therapy for hemophilia gets FDA approvalU.S. health regulators have approved the first gene therapy for hemophilia, a blood-clotting disorder with few treatment options
Read more »
FDA approves most expensive drug ever, a $3.5 million-per-dose gene therapy for hemophilia BU.S. health regulators on Tuesday approved the first gene therapy for hemophilia, a $3.5 million one-time treatment for the blood-clotting disorder.
Read more »
FDA approves gene therapy for hemophiliaThe FDA approved a gene therapy for hemophilia — the latest in a series of decisions to advance pricey, personalized treatments that bring new hope to patients, along with cost concerns to the health system.
Read more »
FDA Approves First Gene Therapy for Hemophilia BEtranacogene dezaparvovec is the first gene therapy option for adults with hemophilia B who use factor IX prophylaxis and have repeated, spontaneous bleeding episodes. This one-time gene therapy has a list price of $3.5 million.
Read more »
$3.5M gene therapy for hemophilia gets FDA approvalU.S. health regulators on Tuesday approved the first gene therapy for hemophilia, a $3.5 million one-time treatment for the blood-clotting disorder. The Food and Drug Administration cleared Hemgenix, an IV treatment for adults with hemophilia B, the less common form of the genetic disorder which primarily affects men. Drugmaker CSL Behring announced the $3.5 million price tag shortly after the FDA approval, saying its drug would ultimately reduce health care costs because patients would have fewer bleeding incidents and need fewer clotting treatments.
Read more »